<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02310295</url>
  </required_header>
  <id_info>
    <org_study_id>12029-2008</org_study_id>
    <nct_id>NCT02310295</nct_id>
  </id_info>
  <brief_title>Prospective, Randomized Clinical Trial Comparing Macular Photocoagulation With or Without Intravitreal Bevacizumab or Triamcinolone for the Treatment of Diabetic Macular Edema</brief_title>
  <acronym>IBeTA</acronym>
  <official_title>Bevacizumabe e Acetato de Triancinolona Intra-vítreo Associados à Laserterapia em Pacientes Com Edema Macular diabético (IBeTA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: To compare the effects of macular photocoagulation with or without intravitreal&#xD;
      bevacizumab (IVB) or triamcinolone (IVTA) for the treatment of diabetic macular edema (DME).&#xD;
      Casuistic and Methods: 58 eyes of 44 patients with diffuse DME were randomized to receive&#xD;
      either IVB + focal/grid laser (IVB-Laser, n=19), IVTA + focal/grid laser (IVTA-Laser, n=16)&#xD;
      or focal/grid laser alone (Laser, n=23). Ophthalmic evaluation, including best-corrected&#xD;
      visual acuity (BCVA), intraocular pressure (IOP) and central macular thickness (CMT) were&#xD;
      performed at baseline and monthly for 12 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Central subfield macular thickness</measure>
    <time_frame>12 months</time_frame>
    <description>retinal thickness measured with optical coherence tomography</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual acuity</measure>
    <time_frame>12 months</time_frame>
    <description>Best corrected visual acuity</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">45</enrollment>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>IVB-Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Bevacizumab combined with focal laser therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IVTA-Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Triamcinolone combined with focal laser therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Laser</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>focal laser therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Laser</intervention_name>
    <description>focal macular laser therapy</description>
    <arm_group_label>IVB-Laser</arm_group_label>
    <arm_group_label>IVTA-Laser</arm_group_label>
    <arm_group_label>Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Intravitreal injection of Bevacizumab</description>
    <arm_group_label>IVB-Laser</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone Acetonide</intervention_name>
    <description>Intravitreal injection of Triamcinolone Acetonide</description>
    <arm_group_label>IVTA-Laser</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. clinically significant diabetic macular edema (DME) with diffuse leakage involving the&#xD;
             center of the fovea, with DME greater than 275 microns in OCT examination&#xD;
&#xD;
          2. BCVA between 0.3 LogMAR (logarithm of smaller angle of visual resolution) (20/40) and&#xD;
             1.6 LogMAR (20/800)&#xD;
&#xD;
          3. signed of inform Consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. HbA1c levels greater than 10%&#xD;
&#xD;
          2. thromboembolic event history (including myocardial infarction and stroke)&#xD;
&#xD;
          3. vitreo-macular traction on OCT&#xD;
&#xD;
          4. coagulation disorders&#xD;
&#xD;
          5. macular ischemia on fluorescein angiography examination&#xD;
&#xD;
          6. proliferative diabetic retinopathy that required treatment&#xD;
&#xD;
          7. eye surgery&#xD;
&#xD;
          8. history of ocular hypertension or glaucoma&#xD;
&#xD;
          9. any ocular pathology which in the opinion of the investigator, could macular edema or&#xD;
             change the visual acuity during the study period (for example, retinal vascular&#xD;
             occlusion, uveitis or other inflammatory eye disease, neovascular glaucoma)&#xD;
&#xD;
         10. systemic corticosteroid therapy&#xD;
&#xD;
         11. any conditions that could affect the documentation&#xD;
&#xD;
         12. any previous treatment for diabetic macular edema.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>December 2, 2014</study_first_submitted>
  <study_first_submitted_qc>December 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2014</study_first_posted>
  <last_update_submitted>December 5, 2014</last_update_submitted>
  <last_update_submitted_qc>December 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Andre Messias</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Diabetic retinopathy</keyword>
  <keyword>Macular edema</keyword>
  <keyword>Anti-VEGF</keyword>
  <keyword>Triamcinolone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Triamcinolone Acetonide</mesh_term>
    <mesh_term>Triamcinolone hexacetonide</mesh_term>
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Triamcinolone diacetate</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 9, 2021</submitted>
    <returned>March 2, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

